Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
14hon MSN
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
A Burnley resident is highlighting three back streets in Burnley that they say are riddled with drugs and rubbish.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback